Literature DB >> 10372279

Hepatobiliary manifestations of inflammatory bowel disease.

V Raj1, D R Lichtenstein.   

Abstract

PSC is the most common of the clinically significant hepatobiliary diseases seen in association with IBD, with an incidence that varies from 2.5% to 7.5%. Conversely, 50% to 75% of patients with PSC have IBD. This high degree of association suggests a common pathogenetic mechanism; however, no causal relationship has been established. The etiopathogenesis of PSC remains poorly understood, despite a large number of studies looking at differing hypotheses. The diagnosis is usually established by cholangiography. Liver biopsy can sometimes be helpful in diagnosing pericholangitis. There is a significant overlap of the histology with chronic hepatitis. Serum markers have been studied for diagnosing PSC, particularly for early diagnosis of cholangiocarcinoma, but none have shown the high sensitivity and specificity needed to use them clinically. PSC usually progresses insidiously and eventually leads to cirrhosis. Despite progress in early recognition, optimal management of patients with PSC remains a challenge requiring a multidisciplinary approach among hepatologists, endoscopists, surgeons, and interventional radiologists. Colectomy for ulcerative colitis does not alter the natural history of PSC. There is a high (10% to 15%) incidence of cholangiocarcinoma in patients with PSC. This incidence along with the risk of colon cancer in patients with ulcerative colitis makes it necessary to follow these patients closely. A number of pharmacologic therapies have been evaluated, but none has proven successful in slowing the progression of PSC or prolonging survival. Endoscopic therapy has a proven utility in treating complications of recurrent cholangitis or worsening jaundice in the setting of a dominant stricture, but endoscopy has not been shown to improve survival or decrease the need for liver transplantation. Liver transplantation is life-saving for patients with advanced PSC. Pericholangitis, gallstones, and chronic hepatitis are additional disorders noted in association with IBD, but they are much less common and easier to manage than PSC.

Entities:  

Mesh:

Year:  1999        PMID: 10372279     DOI: 10.1016/s0889-8553(05)70067-4

Source DB:  PubMed          Journal:  Gastroenterol Clin North Am        ISSN: 0889-8553            Impact factor:   3.806


  9 in total

1.  Unusual development of hepatocellular carcinoma in a patient with Crohn's disease.

Authors:  M L Borum
Journal:  Dig Dis Sci       Date:  2001-10       Impact factor: 3.199

Review 2.  Clinical aspects and pathophysiology of inflammatory bowel disease.

Authors:  Barbara A Hendrickson; Ranjana Gokhale; Judy H Cho
Journal:  Clin Microbiol Rev       Date:  2002-01       Impact factor: 26.132

3.  [Intestinal inflammatory disease with cholestasis].

Authors:  T Meindl; C Becker-Gaab; K J Pfeifer; M F Reiser
Journal:  Radiologe       Date:  2006-07       Impact factor: 0.635

Review 4.  Development of primary biliary cirrhosis in a patient with Crohn's disease: a case report and review of the literature.

Authors:  Hyun Joo Jang; Geun Sook Kim; Chang Soo Eun; Sea Hyub Kae; Woo Young Jang; Jin Lee
Journal:  Dig Dis Sci       Date:  2005-12       Impact factor: 3.199

Review 5.  Pediatric inflammatory bowel disease.

Authors:  Karen-A Diefenbach; Christopher-K Breuer
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

Review 6.  Hepatobiliary complications of inflammatory bowel disease.

Authors:  David R Lichtenstein
Journal:  Curr Gastroenterol Rep       Date:  2011-10

7.  Sonographic detection of perihepatic lymphadenopathy is an indicator for primary sclerosing cholangitis in patients with inflammatory bowel disease.

Authors:  Tim O Hirche; Jan Russler; Barbara Braden; Gudrun Schuessler; Stefan Zeuzem; Till Wehrmann; Hans Seifert; Christoph F Dietrich
Journal:  Int J Colorectal Dis       Date:  2004-04-15       Impact factor: 2.571

8.  Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease.

Authors:  Carsten Gnewuch; Gerhard Liebisch; Thomas Langmann; Benjamin Dieplinger; Thomas Mueller; Meinhard Haltmayer; Hans Dieplinger; Alexandra Zahn; Wolfgang Stremmel; Gerhard Rogler; Gerd Schmitz
Journal:  World J Gastroenterol       Date:  2009-07-07       Impact factor: 5.742

9.  Sclerosing pancreatitis presenting as a periampullary tumour.

Authors:  A K Sahajpal; C M Vollmer; A Pollett; S Gallinger
Journal:  HPB (Oxford)       Date:  2003       Impact factor: 3.647

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.